Blood group genotyping systems help determine blood groups in individuals who may not be able to be typed with traditional blood grouping methods due to recent transfusions, autoantibodies, or other limitations.
Blood group genotyping for human erythrocyte antigens overcomes blood grouping limitations by looking directly into the DNA sequence and thereby avoiding any donor cell or patient antibody interference. Additional benefits of blood group genotyping include improved transfusion compatibility and reduced alloimmunization.
A multiplex blood group genotyping family of products based on Luminex technology; including kits for the main allelic variants of red blood cells (ID CORE XT, ID RHD XT), human platelet antigens (ID HPA XT), a positive control for ID CORE XT (ID CORE CONTROL), and an accompanying software (BIDS XT).
Efficient
Quickly progress from DNA to results with a fast and easy operating procedure.
Flexible
Accommodate both donor and patient typing with BLOODchip ID’s throughput, flexibility, and antigen panels.
Reliable
Support safer transfusion therapy for patients with a fast and effective solution.
Traceability
Keep track of activity with BIDS XT’s comprehensive database for samples, clinical information, and test results.